Live Terminal | Security Analysis of GBY.DE
TERMINAL beta
Version: 0.1
Timestamp: 1708729632.472918
Options
100220.KS
52.83%
1809.TW
51.88%
006220.KS
49.51%
0756.HK
49.35%
B7J.DE
48.43%
0T8B.F
-39.43%
009310.KS
-40.63%
SZGPF
-42.69%
GOLL4.SA
-52.40%
HGEN.L
-53.56%
AAPL $182.88 -0.81%
AMD $176.41 -3.00%
AMZN $174.58 0.00%
BRK-B $417.87 0.65%
GOOG $145.44 0.08%
IBM $185.76 0.84%
INTC $43.28 0.71%
JNJ $161.87 0.89%
JPM $184.12 0.57%
META $488.06 0.40%
MSFT $410.31 -0.33%
O $53.27 0.85%
TSLA $195.04 -1.20%
WMT $176.24 0.47%
QQQ $437.06 -0.2306%
TLT $93.88 1.3441%
VUAA.DE $88.65 0.3918%
VUSA.DE $89.31 0.4025%
FJPR.L $5.64 1.5565%
VWRP.L $97.83 0.1638%
VWRL.L $98.54 0.1626%
EMGU.L $3.60 -0.1111%
RDVY $52.46 0.4211%
FLOT $50.99 0.0098%
SCHZ $45.73 0.3952%
IBB $138.22 0.7655%
C020.DE $21.34 0.0000%
DFAX $24.72 0.0862%
MEUD.PA $226.19 0.4173%
LYP6.DE $226.20 0.4440%
IDWR.L $71.10 0.4521%
IQQW.DE $65.72 0.3972%
EXS1.DE $145.70 0.2477%
XESC.L $6865.00 0.1240%
DFAU $35.28 0.1783%
ACWV $104.09 0.3277%
VHYD.L $63.92 0.2746%
VGWD.DE $59.24 0.5602%
FXKZ.ME $303.00 0.0000%

Latest articles

No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.

Sentiment statistics ?
GBY.DE
μ null
null
null

Financial Histories

Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.

Overview
GBY.DE
Latest Performance
GBY.DE$5.05
$-0.20 • -3.81%
GBY.DE
Price 5.05
Change Pct -3.81
Change Abs -0.20
Market Cap 884.7 million
Eps -1.15
Pe Ratio -4.38
Outstanding Shares 175.1 million
Volume 100
Avg Volume 180
Industry Biotechnology
Sector Name Health Care
Country Short Name US
Announcement Earnings 2024-02-20 21:00:00+00:00
All metrics in USD or %.
Dividends

There is no dividend data to display. Refer our Dividend calendar for other accurate data.

Risk Profiles

Please sign up and become a member to view all risk profiles.

Competitors/Peer Groups

The peer analysis is for none of your tickers available

Focus

The 'Focus' Area is meant to be an One-Pager about all Important Insights, Risks and Opportunities to solely analyze a single corporate.

Company descriptions
GBY.DE

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A;